TrialFind
Saved trials

Filters

Status

Phase

Age group

TrialFind

Data sourced from ClinicalTrials.gov. Always consult a healthcare provider before enrolling.

PrivacyData sourcesRegulatory infoContact
CompletedN/A

Efficacy of a Non-invasive Device for Alleviation of Parkinson's Disease Symptoms

Investigation efficacy of a non-invasive wearable electrostimulator device where the supplementary motor area, premotor area and/or subthalamic nucleus are stimulated bilaterally and extracranially.

Istanbul, Turkey (Türkiye)+1 moreView details
CompletedN/A

Osteopathic Manual Treatment Parkinson's Disease and Truncal Dystonia

This study will determine if posture and heart rate variability will significantly improve in Parkinsons disease with camptocormia after osteopathic manual treatments dystonia.

Old Westbury, New York, United StatesView details
UnknownPhase 1

Phase I Open-label Study of Low-dose Ketamine Infusion Treatment in Levodopa-Induced Dyskinesia in Parkinson's Disease

The primary objective is to determine the tolerability and efficacy of a low-dose ketamine infusion for the treatment of Levodopa-Induced dyskinesias (LID), both acutely and during post-infusion evaluation (week 2-6), as measured by a chang

Tucson, Arizona, United StatesView details
CompletedPhase 2

A Study in Parkinson's Disease in Patients With Moderate to Severe Dyskinesia

The current study will explore the efficacy, safety and tolerability of 2 dose combinations of JM-010 to determine the optimal doses of each component to be studied in confirmatory clinical trials.

Toulouse, France+4 moreView details
CompletedPhase 3

Efficacy and Safety of BF2.649 in Excessive Daytime Sleepiness (EDS) in Parkinson's Disease

To compare the efficacy of BF2.649 over placebo (12 week Double-Blind Phase) and assess the long term safety and the efficacy maintenance(9 months Open-Label Extension Phase) of BF2.649 in the improvement of excessive daytime sleepiness in

Marburg, GermanyView details
CompletedPhase 4

Anti-Diabetic Medications to Fight PD and LBD

The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.

Jacksonville, Florida, United StatesView details
UnknownN/A

Group Therapy With Transcranial Direct Current Stimulation in Patients With Parkinson's Disease

To determine the effectiveness of group therapy along with transcranial direct current (tDCS) stimulation on motor symptoms, balance and quality of life in patients with Parkinson's disease(PD). 128 patient with PD will be recruited by the

Multiple locationsView details
CompletedPhase 3

Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia

This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once night

Fountain Valley, California, United States+50 moreView details
Completed

Usability of Levodopa Cyclops™ vs INBRIJA® in Parkinson's Patients

Currently there is one Levodopa inhaler on the market, the INBRIJA® inhaler. When looking at the user instructions for the INBRIJA®, multiple steps are necessary including preparing and cleaning the inhaler.

Groningen, NetherlandsView details
CompletedPhase 1 / Phase 2

N-Acetylcysteine for Neuroprotection in Parkinson's Disease

The overall objective of this developmental/exploratory study is to use noninvasive proton magnetic resonance spectroscopy (1H MRS) to assess (a) whether brain levels of the antioxidant glutathione (GSH) are decreased in vivo, as has been f

New York, New York, United StatesView details
RecruitingN/A

Experimental Pain in Parkinsons

Study comparing pain intensity and discomfort in patients with Parkinson´s disease and healthy controls during inducement of mechanical, thermal, and chemical experimental pain

Aarhus, DenmarkView details
CompletedPhase 4

The Effect of Rasagiline on Cognition in Parkinson's Disease

While Parkinson's disease has historically been defined in terms of its motor symptomatology, studies have shown that non-motor deficits form an important part of the syndrome. Cognitive deficits can occur even in the early stages of Parkin

Providence, Rhode Island, United StatesView details
CompletedN/A

Telehealth Psychotherapy for Depression in Parkinson's Disease

Depression is a prevalent non-motor symptom of Parkinson's disease (PD). Cognitive-behavioral therapy (CBT) has been shown to be an effective treatment for depression in PD.

Boston, Massachusetts, United StatesView details
CompletedN/A

Effects of rTSMS Associated With Treadmill Training in Patients With Parkinson's Disease

Gait changes appear and become the main cause of disability, loss of independence, falls, fractures and reduced quality of life for patients with Parkinson Disease. Optimal gait management is complex and challenging.

São Paulo, São Paulo, BrazilView details
CompletedN/A

Stress Management and Resiliency Training Program for Parkinson's Disease

SMART-PD is an 8-session program designed to decrease the physiological, emotional, cognitive and behavioral effects of stress in participants with Parkinson's disease and their caregivers by teaching cognitive-behavioral techniques and rel

Stony Brook, New York, United StatesView details
By invitation

Circuit-Based Deep Brain Stimulation for Parkinson's Disease; Udall Clinical Core

The goal of this project is to provide comprehensive longitudinal assessments of a cohort of PD patients before, during, and after DBS surgery, including neurological, neurophysiological, and neuropsychological data.

Minneapolis, Minnesota, United StatesView details
Not yet recruitingN/A

Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology

This study aimed to determine the efficacy of amyloid clearance of lecanemab in patients with Parkinson's disease (PD) with amyloid co-pathology. Lecanemab, an anti-amyloid monoclonal antibody, was apporoved by the US FDA in July 2023 and i

Seoul, South KoreaView details
RecruitingN/A

User-friendliness of a Portable Driving Simulator

The use of simulators to retrain driving skills of patients with stroke, Parkinson's disease (PD), or multiple sclerosis (MS) is very limited because of cost, space required, and incidence of simulator sickness in high fidelity simulators.

Kansas City, Kansas, United StatesView details
CompletedN/A

Dietary Intervention and Gastrointestinal Function in Patients With Parkinson's Disease

In this prospective, intervention study, participants with diagnosed Parkinson's disease will be instructed to follow a Mediterranean diet for five weeks. Gut permeability will be assessed using food-grade sugar molecules.

Gainesville, Florida, United StatesView details
CompletedN/A

Effects of Complementary Therapies in People With Mild to Moderate Parkinson's Disease

The aim of this study was to compare the effects of Hatha Yoga versus Stretching on physical outcomes, quality of life, physical activity and motor examination in persons with Parkinson Disease. The hypothesis of this study is that Hatha Yo

Leioa, Bizkaia, SpainView details
Load more trials